Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
146 hedge funds and large institutions have $1.73B invested in Akero Therapeutics in 2022 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 53 increasing their positions, 27 reducing their positions, and 16 closing their positions.
427% more capital invested
Capital invested by funds: $329M → $1.73B (+$1.41B)
206% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 16
133% more funds holding in top 10
Funds holding in top 10: 3 → 7 (+4)
96% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 27
29% more funds holding
Funds holding: 113 → 146 (+33)
5% more ownership
Funds ownership: 104.87% → 109.88% (+5%)
44% less call options, than puts
Call options by funds: $23.7M | Put options by funds: $42.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$83.9M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$47.8M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$34.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$15.4M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$14.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
-$24.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$21.7M |
| 3 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$18.9M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$10.4M |
| 5 |
Millennium Management
New York
|
-$4.92M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$769 | -69,653 | Closed |
|
|
KCM
152
Karp Capital Management
Sausalito,
California
| – | -$331K | -35,000 | Closed |
|
|
EGM
153
Engineers Gate Manager
New York
| – | -$273K | -28,899 | Closed |
|
|
DTL
154
Dynamic Technology Lab
Singapore
| – | -$266K | -28,155 | Closed |
|
155
Two Sigma Advisers
New York
| – | -$210K | -22,200 | Closed |
|
|
MAM
156
Martingale Asset Management
Boston,
Massachusetts
| – | -$145K | -15,316 | Closed |
|
|
XT
157
XTX Topco
George Town,
Cayman Islands
| – | -$126K | -13,305 | Closed |
|
158
HSBC Holdings
London,
United Kingdom
| – | -$124K | -13,064 | Closed |
|
|
QT
159
Quantbot Technologies
New York
| – | -$95K | -10,100 | Closed |
|
|
PHK
160
Point72 Hong Kong
Hong Kong
| – | -$4K | -398 | Closed |
|
161
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | -53 | Closed |
|
AKRO Hedge Fund Activity: Q3 2022 in Review
146 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q3 2022, worth a combined $1.73B — up 427% from $329M a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new AKRO positions and 16 closed out — a net gain of 33 holders — while 53 added to existing stakes and 27 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $83.9M. The largest seller was venBio Partners, cutting an estimated $24.1M.
- 146 institutional investors held Akero Therapeutics (AKRO) as of Q3 2022, up from 113 in Q2 2022.
- Funds reported $1.73B of Akero Therapeutics stock for Q3 2022, up 427% quarter-over-quarter.
- 49 funds opened new Akero Therapeutics positions in Q3 2022 and 16 closed out, a net change of +33 holders.
- The largest Akero Therapeutics buyer in Q3 2022 was Janus Henderson Group, an estimated $83.9M added.
- The largest Akero Therapeutics seller in Q3 2022 was venBio Partners, an estimated $24.1M sold.
Based on aggregated 13F filings for Q3 2022.